Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Renal Insufficiency, Chronic 1

Interventions

Specimen Handling 34Magnetic Resonance Spectroscopy 22Biopsy 20Cyclophosphamide 11venetoclax 7Nivolumab 6Azacitidine 6pembrolizumab 5Etoposide 5Cisplatin 5Bevacizumab 5fludarabine phosphate 4fludarabine 4Vincristine 4Taxes 4Surgical Procedures, Operative 4Radiotherapy, Intensity-Modulated 4Radiosurgery 4Radiation 4Doxorubicin 4Cetuximab 4durvalumab 3decitabine and cedazuridine drug combination 3X-Rays 3Tacrolimus 3Surveys and Questionnaires 3Prednisone 3Platinum 3Leucovorin 3Irinotecan 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Quillaja Saponins × 1 year × Clear all
NCT06741072 2026-04-21

BZLF1 Peptide Vaccine (OSU-2131) With QS-21 for the Prevention of Epstein-Barr Virus Related Cancer in Patients Awaiting Solid Organ Transplants

Ohio State University Comprehensive Cancer Center

Phase 1 Suspended
55 enrolled

Renal Insufficiency, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡